Gastric or Gastroesophageal Junction Adenocarcinoma

• CLINICAL_TRIALS trial_result · 2022-04-06
  Clinical Trial Update: SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma [Phase 2]

  Phase 2 trial evaluating SOX chemotherapy combined with sintilimab and trastuzumab versus SOX alone in perioperative treatment of HER2-posit…

• CLINICAL_TRIALS trial_result · 2021-04-14
  Clinical Trial Update: PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]

  Phase 2 trial evaluating a PD-1 antibody plus XELOX in first-line gastric or gastroesophageal junction adenocarcinoma with elevated AFP; cur…

• CLINICAL_TRIALS trial_result · 2019-12-19
  Clinical Trial Update: Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer [Phase 1, Phase 2]

  Phase 1/2 trial evaluating sintilimab in combination with IBI310 for EBV-positive gastric cancer/GEJ adenocarcinoma; efficacy and safety dat…